News | January 24, 2026
Akums bags key EU GMP certifications for 2 Haridwar plants
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This marks the second indication for which gumokimab has gained NDA review acceptance
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Subscribe To Our Newsletter & Stay Updated
